<DOC>
	<DOCNO>NCT00739999</DOCNO>
	<brief_summary>To evaluate pharmacokinetics , pharmacodynamics , safety tolerability atorvastatin child adolescent heterozygous familial hypercholesterolemia</brief_summary>
	<brief_title>8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Genetically confirm heterozygous familial hypercholesterolemia ( HeFH ) LDL great equal 4 mmol/L baseline Evidence history clinically significant disease , homozygous familial hypercholesterolemia ( FH )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>heterozygous familial hypercholesterolemia ( HeFH ) ; atorvastatin ; pediatric</keyword>
</DOC>